Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;7(6):e2101.
doi: 10.1002/cnr2.2101.

Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study

Senichiro Yanagawa  1 , Kazuaki Tanabe  2 , Mikihiro Kano  3 , Ryuichi Hotta  4 , Yoshihiro Saeki  5 , Nobuaki Fujikuni  6 , Hideki Ohdan  5 ; Hiroshima Surgical Study Group of Clinical Oncology (HiSCO)
Collaborators, Affiliations
Multicenter Study

Clinicopathological features of hepatoid adenocarcinoma of the stomach: A multicenter retrospective study

Senichiro Yanagawa et al. Cancer Rep (Hoboken). 2024 Jun.

Abstract

Background: Hepatoid adenocarcinoma of the stomach (HAS) is a rare and aggressive subtype of gastric cancer (GC), accounting for less than 1% of all cases. It is characterized by frequent liver metastasis recurrence and a poorer prognosis than conventional GC. However, established treatment guidelines for HAS are currently not available.In this report, we present the results of a clinicopathological study of 19 patients diagnosed with HAS, including seven patients with liver metastasis, conducted by the Hiroshima Surgical Study Group of Clinical Oncology (HiSCO) between 2016 and 2018.

Aims: The aim of the study was to retrospectively observe the outcomes of HAS with gastrectomy and hepatectomy for liver metastasis and determine relevant prognostic factor. We also examined the criteria and outcomes of hepatectomy for liver metastasis and aimed to suggest the optimal treatment for HAS, including chemotherapy.

Methods and results: A total of 2147 patients underwent gastrectomy for GC at HiSCO-affiliated institutions during the study period; 19 patients, all male with a mean age of 70.9 years, were diagnosed with HAS by hematoxylin-eosin and immunohistochemical staining. Patients underwent gastrectomy at varying pathological stages: six at Stage I, three at Stage II, seven at Stage III, and three at Stage IV. Ten patients received postoperative chemotherapy and the 5-year survival rate was 67.7% after gastrectomy. Among the seven patients with pre or postoperative liver metastasis, five patients underwent hepatectomy. Although one patient had recurrence, the 3-year survival rate was 100% after hepatectomy.

Conclusion: Contrary to previous reports suggesting a 3-year survival rate of approximmately 30% for HAS, our findings indicate that the prognosis for HAS may not be as poor as reported previously. This study contributes valuable insights into the management and potential treatment strategies for HAS.

Keywords: chemotherapy; gastrectomy; hepatectomy; hepatoid adenocarcinoma of the stomach; liver metastasis.

PubMed Disclaimer

Conflict of interest statement

The authors have stated explicitly that there are no conflicts of interest in connection with this article.

Figures

FIGURE 1
FIGURE 1
Flow chart of participant inclusion in the present study.
FIGURE 2
FIGURE 2
Overall survival after gastrectomy: 1‐year survival rate 100%, 3‐year survival rate 78.9%, and 5‐year survival rate 67.7%.
FIGURE 3
FIGURE 3
Comparison of survival rate between pStage I and II, III, and IV. There was no statistically significant difference in the 5‐year survival rate between the two groups (p = .205).
FIGURE 4
FIGURE 4
Overall survival after hepatectomy: 3‐year survival rate of five cases was 100%.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zou M, Li Y, Dai Y, et al. AFP‐producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review. Onco Targets Ther. 2019;12:7649‐7654. doi:10.2147/OTT.S216501 - DOI - PMC - PubMed
    1. Søreide JA. Therapeutic approaches to gastric hepatoid adenocarcinoma: current perspectives. Ther Clin Risk Manag. 2019;15:1469‐1477. - PMC - PubMed
    1. Bosman FT, Carneiro F, Hruban RH, Theise ND. Tumours of the Stomach. WHO Classification of Tumours of the Digestive system. Vol 3. 4th ed. WHO; 2010:45‐58.
    1. Zeng XY, Yin YP, Xiao H, et al. Clinicopathological characteristics and prognosis of hepatoid adenocarcinoma of the stomach: evaluation of a pooled case series. Curr Med Sci. 2018;38:1054‐1061. doi:10.1007/s11596-018-1983-1 - DOI - PubMed
    1. Xia R, Zhou Y, Wang Y, Yuan J, Ma X. Hepatoid adenocarcinoma of the stomach: current perspectives and new developments. Front Oncol. 2021;11:633916. doi:10.3389/fonc.2021.633916 - DOI - PMC - PubMed

Publication types

MeSH terms